Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

CB-103

Stage Phase 1/2

Sponsor Cellestia Biotech

Route oral (not re-verified)

Class pan-NOTCH transcription inhibitor

Mechanism blocks NOTCH transcription complex

Target NOTCH1 to 4 (gamma secretase)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03422679

CB-103 (pan-NOTCH inhibitor): Hanna GJ et al. Cancer Res Commun 2023, doi 10.1158/2767-9764.CRC-23-0333 (PMC10501326; publication not re-opened this run) and registry NCT03422679 (terminated for business reasons, n 79, no dose-limiting toxicities in any cohort, results posted 01.16.2024). No efficacy figure from this source is used.

Brief source A26

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03422679

A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05774899

A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

CB-103 Phase 1/2 (terminated)

Registry NCT03422679

Phase Phase 1/2

Status Terminated

Enrollment 79

Start 2017-12-05

Primary completion 2022-11-11

Study completion 2022-11-11

CB-103 + lenvatinib or abemaciclib

Registry NCT05774899

Phase Phase 1/2

Status Recruiting

Enrollment 32

Start 2023-06-01

Primary completion 2027-06-01

Study completion 2028-06-01

Catalyst Primary completion. 06.01.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.